Nathan Collins discusses how integrating AI with the SynFini automated chemistry platform is poised to shape the future of drug discovery and development. Learn more about SynFini at: https://www.sri.com/case-studies/synfini
Nathan Collins is the Chief Strategy Officer of SRI Biosciences in Menlo Park, CA. In part two of this episode of The Dish TV they discuss how integrating artificial intelligence with the SynFini™ platform will enable better molecule design, more efficient iteration, and faster development of new drug treatments.
— SRI’s The Dish TV highlights the most special part of SRI—our people. Join Host Reenita Hora, Head of Marketing and Communications, for casual conversations with guests from across our institute about what brought them to and keeps them at SRI, as well as the latest world-changing innovations to come out of their divisions. At SRI, we’re inventing a better future together.
